Although previous clinical trials have suggested that repetitive transcranial magnetic stimulation (rTMS) has a significant antidepressant effect, the results of these trials are heterogeneous. We hypothesized that individual patients' characteristics might contribute to such heterogeneity. Our aim was to identify predictors of antidepressant response to rTMS. We pooled data from six separate clinical trials conducted independently, which evaluated the effects of rapid rTMS of the left dorsolateral prefrontal cortex in patients with major depression. We investigated 195 patients with regard to demographic, depression and treatment characteristics, psychiatric and drug history. Results showed that age and treatment refractoriness were significant negative predictors of depression improvement when adjusting these variables to other significant predictors and confounders. These findings were not confounded by methodological differences from the six studies, as the results were adjusted for the study site. In conclusion TMS antidepressant therapy in younger and less treatment-resistant patients is associated with better outcome.
Introduction
Major depressive disorder (MDD) is a serious medical illness and a leading cause of disability worldwide (Ustun et al., 2004) . The most used therapy for MDD is pharmacological treatment ; however, this treatment is often associated with adverse events. A nonpharmacological option is electroconvulsive therapy (ECT). Although being the most efficacious treatment for MDD, ECT is associated with an anaesthetic risk, memory changes and social stigma (Fink, 2001) . A non-invasive form of brain stimulation -repetitive transcranial magnetic stimulation (rTMS) -that is not associated with the adverse effects of ECT has been shown to be efficacious for the treatment of depression (see meta-analyses : Burt et al., 2002 ; Holtzheimer et al., 2001 ; Martin et al., 2003) . Several studies have shown that this treatment can induce antidepressant effects with few, usually mild adverse effects (Conca et al., 1996 ; Eschweiler et al., 2000 ; George et al., 1997 George et al., , 2000 Grunhaus et al., 2000 ; Holtzheimer et al., 2001 ; Pascual-Leone et al., 1996 ; Pridmore et al., 2000) . However, other studies have failed to show clinical improvements in depressed patients after rTMS treatment (Hausmann et al., 2004 ; Padberg et al., 1999) . Such variability could be explained by the random variability of the 'true ' TMS effect, particularly because most published TMS studies to date are small and lack adequate statistical power ; or alternatively by different patients' characteristics. In fact, Gershon et al. (2003) , in a literature review, conclude that, although TMS shows promise as a novel antidepressant treatment, 'large-scale studies are needed to identify patient populations most likely to benefit from rTMS treatment ' (Gershon et al., 2003) . We, therefore, pooled data from six clinical trials to investigate the predictors of the TMS antidepressant treatment based on patients' and treatment characteristics, such as the items of the Hamilton Depression Rating Scale (HAMD), age, gender, psychiatric and drug history and TMS parameters.
Methods

Subjects
The data were collected for 195 patients diagnosed with MDD. The diagnosis of MDD was made using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID ; First et al., 1997 ) by a trained interviewer. These patients were pooled from six studies that evaluated the antidepressant effects of 10 d of high-frequency rTMS applied to the left prefrontal cortex. In one of the studies (Ontario), the data presented were those related to the open-label treatment with real rTMS. The other five studies were randomized double-blind studies. These studies were done in Boston (Harvard Medical School), Innsbruck (Medical University Innsbruck), Tel Aviv (Tel Aviv University), Hamilton, Ontario (McMaster University) and Sao Paulo (two studies -University of Sao Paulo). The numbers and characteristics of patients in each study are summarized in Tables 1 and 2 . All six studies were conducted on male or female patients older than 18 years. Study protocols had been reviewed and approved by the ethical review board at each centre, in accordance with the principles of the Declaration of Helsinki, and all patients provided written informed consent.
TMS clinical trials design
Five of these studies were randomized, double-blind clinical trials and one of them was an open-label study (Ontario site). Patients were scored on the HAMD by a rater who remained blinded to the treatment type of the patient (except for the Ontario study). The 10 rTMS treatment sessions were given only on weekdays and were completed in a period of 2 wk. Patients were re-evaluated following the last session of rTMS (at the end of week 2). Repetitive TMS was administered using a figure-of-eight coil and applied over the left dorsolateral prefrontal cortex (5 cm anterior to the motor spot that elicited motor-evoked potentials in either the abductor pollicis brevis or the first interosseous dorsalis muscle of the right hand). However these studies used different parameters of stimulation (see Table 1 ). We addressed the influence of these parameters' difference in our final model.
Outcome measure
We used the HAMD as this instrument has been widely used in efficacy studies of antidepressant treatments (Endicott et al., 1981 ; Elkin et al., 1985 ; Williams, 1988) . The version of the instrument utilized in these studies contains the following items : depressed mood, feelings of guilt, suicide, insomnia early, insomnia middle, insomnia late, work and activities, retardation, agitation, anxiety/psychic, anxiety/somatic, somatic symptoms/GI, somatic symptoms/general, genital symptoms, hypochondriasis, loss of weight, and insight.
Statistical methods
The following independent variables were selected from these studies : age, gender (M/F), study site (Boston, Innsbruck, Sao Paulo 1, Sao Paulo 2, Tel Aviv and Ontario), baseline scores for the Hamilton Depression Rating Scale (b-HAMD), post-treatment change in HAMD [d-HAMD ( %)], the scores of each HAMD baseline item, TMS frequency, number of pulses, TMS intensity, depression duration, medication use and treatment refractoriness. We treated all HAMD items as ordinal variables. Gender, medication (antidepressant use : yes/no) and treatment refractoriness (yes/no) were binary variables ; location was categorical and age, TMS frequency, number of pulses, TMS intensity, baseline and HAMD changes ( %) were treated as continuous variables. Our goal was to model the relationship between these predictors and the change in the Hamilton scores (d-HAMD) using a linear regression analysis. Although the test for normality (Wilk-Shapiro) indicated that our outcome variable (HAMD change) was marginally significant (0.03), we considered this variable as normally distributed using the central limit theorem for large sample sizes as our sample had 195 patients.
Therefore, the use of linear regression was adequate, and means and standard deviation are reported. Although the use of linear regression was adequate, we also performed a new analysis in which we considered treatment response as a categorical variable (responders and remissions) and, therefore, used logistic regression. The first step of modelling was the selection of the covariates. We performed a univariate analysis for each one of our predictors using linear regression with only one variable and we obtained the values for the unadjusted b coefficients and 95 % confidence intervals (CIs). We decided to include in our modelbuilding process all variables that had a p value of <0.1 in order to include potential confounders that did not reach the 0.05 significance level in the univariate analysis.
As the site of the study is an important confounder, it was forced into the final model, although it was not a significant predictor of outcome. Furthermore, as this variable contains six categories that are not ordinal, the categories Sao Paulo 1, Sao Paulo 2, Tel Aviv, Ontario and Innsbruck were dummy coded and included into the model. Therefore, Boston was the reference group for this model since it contained the largest number of patients and provided the best power for the comparisons.
Since we anticipated the different HAMD-related variables to be correlated and thus potentially collinear, we used a forward selection process to build our model. This methodology is well-suited to exclude collinear terms, but risks excluding non-significant confounders. To correct for this caveat, we examined the potential confounding effect of each one of the excluded variables by adding them individually to the model. Confounding was defined by changes of ¡10 % or higher in the b coefficient of any variable from the forward selection model. Confounders were included in our final model.
Initially, we ran two models. In one of them (model 1), we used the 17 items of the HAMD and for the other model (model 2), we used the items of the HAMD collapsed in six categories as follows : anxiety (HAMD, items 10, 11), cognition (HAMD, items 9, 10), mood (HAMD, item 1), motor function (HAMD, items 8, 9), social function (HAMD, item 7) and vegetative function (HAMD, items 4, 5, 6, 12, 13, 14, 16) . We decided to pursue this second model as it would provide a more direct clinical interpretation, i.e. it would give a better notion whether symptoms related to anxiety, for instance, rather than item 10 only, would be associated with depression amelioration after 10 d of rTMS. Subsequently, as one of the study sites was a significant predictor when compared to our reference group, we ran a new model without the patients of this group to test the external validity of our model, and also ran a model without the patients of the Ontario study as this was the only open study and included five elderly patients refractory to medication (5-14 antidepressant trials) who could not tolerate ECT (and therefore, could be an outlier for our results due to the severity of treatment refractoriness and age).
Using the same method described for the linear regression model, we built two logistic regression models in which the outcome was either responders (HAMD decrease of o50 %) or remissions (posttreatment HAMD baseline f7). For the remissions model, we had to collapse the study sites to avoid non-convergence as the number of events were low (23) and one group (Sao Paulo 2) had no events, i.e. no remissions, and the other (Ontario) had just two events. We collapsed Sao Paulo 2 and Sao Paulo 1 (Sao Paulo) ; Ontario and Boston (Boston). The regression models were evaluated for goodness of fit using the Hosmer and Lemeshow test.
After defining our model, we checked whether the assumptions for these models were met, testing the normality and constant variance of the residuals. We plotted a graph of the residuals vs. the predicted values. In order to check for potential nonlinear effects of the predictors that could have improved our model, we plotted the residuals against each significant predictor and looked for nonlinear effects. We tested only the significant continuous variables.
To check for potential influential outliers that could have driven our results (as this test is based on normal distribution), the leverage of each subject was calculated using the Hat Diagonal test. Since we defined our model using multiple testing, we increased the risk of type I error and our model could have been overfitted. In order to determine if we had incurred this type of error, we performed the bootstrap test.
We decided to discard patients with missing data for the variables used in our final model. This elimination did not affect our analysis, as the patients that were discarded were small in number and uniformly distributed across the different studies. We eliminated a total of eight patients. The other variables also had few missing data, except for depression duration for which two centres (Ontario, Tel Aviv) could not provide this information. Nevertheless, we did not exclude all these patients, as this variable was not a significant predictor in either univariate or multivariate analysis.
Results Table 1 presents the characteristics of all patients divided by treatment site. This analysis showed that these six groups were significantly different regarding age (p<0.001), b-HAMD (p<0.001), HAMD change (p<0.001), responders (p<0.001), and remissions (p=0.002). Although there was a trend, gender was not significantly different across these six studies (p=0.06). As can be observed in Table 2 (study characteristics), the differences across the studies might reflect the different designs and inclusion criteria of each study and they were addressed in our model as we forced study site into our final model. Table 3 presents the results of the univariate analysis. Interestingly, this analysis demonstrated that TMS parameters investigated in this study, such as treatment frequency, intensity and number of pulses, were either marginally significant [TMS frequency, p=0.05 ; however, TMS frequency dichotomized (f10 Hz or >10 Hz) was not significant, p=0.96] or not significant (TMS intensity, p=0.54, and number of pulses, p=0.12). Our threshold for inclusion in the model was p<0.1. According to this limit, some variables were excluded from further analysis. The following variables were selected for model 1 : age, gender, depression duration, treatment refractoriness, medication, rTMS frequency, b-HAMD (baseline) and HAMD items 4, 7, 10, 11, 13, 17, and for model 2 : age, gender, depression duration, treatment refractoriness, medication, rTMS frequency, b-HAMD and HAMD clusters : anxiety and work. The location, dummy coded into six categories -Sao Paulo 1, Sao Paulo 2, Boston, Tel Aviv, Ontario and Innsbruck -was forced into the models as discussed above.
Since the rTMS parameters are not independent variables as they depend on the study, we also performed a meta-analysis of these data in which we compared the difference in the depression intensity indexed by HAMD between the post-and pretreatment rTMS. In the next step, we performed a meta-regression to analyse if these variables (TMS parameters) were significantly associated with mood improvement and found that none of them were significant predictors of the outcome (TMS intensity, p=0.985 ; number of pulses, p=0.225 ; frequency of stimulation, p=0.813).
We used these variables in our forward selection (the results are presented in Table 4 ). This process resulted in a model with nine variables for model 1 (age, treatment refractoriness, HAMD item 17, gender, Sao Paulo 1, Sao Paulo 2, Innsbruck, Tel Aviv and Ontario). Among these variables, age (p=0.0002), treatment refractoriness (p<0.0001) and Tel Aviv (p=0.0004) were the only significant predictors and the other variables were included because they were either confounders (gender and HAMD item 17) or forced into the model (Sao Paulo 1, Sao Paulo 2, Innsbruck and Ontario) ( reached our threshold of p<0.1 (p=0.02 and p=0.08 respectively) in the univariate analysis and were marginally significant in the multivariate analysis (p=0.024 and p=0.059 respectively). It is interesting to note, however, that the b coefficient for these two variables had a small magnitude compared to the original variable refractoriness included in our original model [13.8 and 11.6 vs. 38.4 respectively for hospitalization, ECT and refractoriness (original variable)]. One of the reasons for such a difference might be the power of these analyses as the information of previous hospitalizations and ECT was not present for all the studies. Because one of the groups (Tel Aviv) was a significant predictor (p=0.0004) when compared to the reference group (Boston), we built another model excluding the patients of this group to test the validity of our model. This new model (model 3 in Table 4 ) yielded the same significant predictors (age, p= 0.0009 ; treatment refractoriness, p<0.0001), but one different confounder (item 4 instead item 17 of HAMD). Gender was still a confounder in this model. Indeed, the Tel Aviv group was increasing the variability of our models (1 and 2) as the R 2 of the model 3, without Tel Aviv, was higher than model 1 and 2 (0.44 vs. 0.39 and 0.38 respectively). Using a similar rationale, we built another model excluding the patients from the Ontario site as this was the only open study included in this analysis. We wanted to test if the results of our study were being confounded by the inclusion of this study. This new model (model 4 in Table 6 ) yielded the same significant predictors : age (p=0.005), treatment refractoriness (p<0.0001), and same confounders (HAMD item 17 and gender). Furthermore, this new model could explain similar data variability compared to models 1 and 2 as the R 2 of this model without Ontario was 0.37 (vs. 0.39 and 0.38 of models 1 and 2 respectively). Furthermore, the residuals for the Ontario site were similar to the other sites, indicating that data from this study behaved similarly to the other sites.
The b coefficient for the significant predictors was x0.52 (95 % CI x0.79 to x0.25) for age and 38.45 (95 % CI 24.69-52.20) for treatment refractoriness. This suggests that an increase in age by 1 yr decreases HAMD response by 0.52 %, when adjusting for the other variables. Likewise patients with treatment refractoriness have a HAMD response 38.45 % smaller than non-refractory patients when adjusting for the other variables.
To test if there was a synergistic effect between age and treatment refractoriness, i.e. age could be a significant predictor only in treatment-refractory patients, we forced the interaction term into the model. The new model (Table 7) with the interaction term disclosed that this variable was not a significant predictor (p=0.75). Therefore, we concluded that there was no synergistic effect between age and treatment refractoriness and did not include the interaction term into the final model (Table 7) .
Finally, we built two logistic regression models in which the outcome was either responders (HAMD decrease of o50 %) or remissions (post-treatment b-HAMD of f7). Using the same process as the linear regression and forcing the study sites into the final model, the significant variables in these two models were the same as in the linear regression models : age and treatment refractoriness (p=0.0042 and p=0.0009 respectively, for responders and p=0.0058 and p=0.0001 respectively, for remissions). The goodness of fit for both models (Hosmer and Lemeshow test) indicate good fit (x 2 =5.26, d.f.=8, p=0.72 for the responders model and x 2 =4.25, d.f.=8, p=0.83 for the remissions model) ( Table 8) .
As sedatives, such as benzodiazepines, might interfere with the effect of rTMS treatment and thus be a significant predictor, we included the variable sedatives in our analysis. We initially tested the use of sedatives (benzodiazepines or non-benzodiazepines with similar effects, such as zolpidem and zopiclone) during rTMS treatment as a categorical variable (yes/no). The univariate analysis showed a significant correlation (p=0.02) ; however, in the multivariate analysis, this variable was no longer significant (p=0.37). Similar results were obtained with this variable treated as a continuous variable (dosage of these drugs using a table of equivalent oral dosages by Ashton, 2002) ; the univariate analysis showed a significant correlation (p=0.005), whereas the multivariate analysis showed that this variable was not significant when adjusting it for other confounders (p=0.77).
Because we were limited to analysing the active rTMS group, the predictors of the antidepressant response to rTMS might be in part due to a placebo effect. Since, in two studies, there was a group of patients that received placebo rTMS, we performed a model including only these patients. Using a forward selection we could not find any significant predictor of the depression improvement after 2 wk of placebo treatment. Indeed, age and refractoriness (highly significant predictors of antidepressant response after active rTMS) were not even close to significance in this model (p=0.91 for age and p=0.48 for refractoriness). A lack of power, however, might account for part of these results as this analysis included 44 patients only. Another method to determine whether the results of our study are due to a general, rather, than a specific effect of rTMS is to build a model including the placebo and active rTMS groups in order to evaluate whether the interaction term between the significant predictors (age and refractoriness) and treatment is significant. We attempted to perform this analysis, however, because only two studies were placebo-controlled ; this analysis did not have enough power. Indeed, the only significant variable in this model was treatment (p=0.0069), therefore, the study of the interaction term is not adequate for our dataset.
In order to rule out that dropouts could be influencing our results, we included the dropouts in our analysis and used an intention-to-treat analysis in which the last evaluation carried out was used for the subsequent evaluations. Only three of these studies reported dropouts (Sao Paulo 2, two patients ; Innsbruck, two patients ; Boston, four patients). The new model revealed the same significant variables (age, p=0.0003 ; refractoriness, p<0.0001) with a slight change in the b coefficient (from x0.52 to x0.51 for age and from 38.4 to 37.3 for refractoriness) (the number of dropouts per study site is given in Table 9 ).
The diagnostic tests for the linear regression showed that the residuals of models 1 and 2 were normally distributed (p value of the Wilk-Shapiro test 0.17 and 0.10 respectively). The plot of the predicted values against the residuals for each model shows no special pattern, therefore, we assumed equal variance.
As one of our main predictors (age) for depression improvement following rTMS is continuous, we checked whether the best relationship of this variable and the outcome was linear. Therefore, we performed the plots of age against the outcome and against the residuals. These plots suggest that the linear relationship was the best approach for age in either models 1 or 2.
When looking for potential outliers, we found five patients having large leverage as detected by the Hat Diagonal test. We excluded these patients from our database and ran the model again. The new model without the outliers showed a slight increase in the R 2 from 0.39 to 0.41 for model 1 and from 0.38 to 0.39 for model 2. There was a slight change in the b coefficient : age changed from x0.52 to x0.49 (model 
Discussion
Our results show that age and medication refractoriness are the two most important predictors of rapid antidepressant response following 2 wk of rTMS treatment. These two variables were significant in all models and remained significant after adjusting for all potential confounders. Therefore, younger and non-refractory patients seem to respond better to rTMS antidepressant treatment. Importantly, the significant variables remained significant after adjusting for the study site. This is particularly important as heterogeneity from different studies is expected and it cannot be entirely accounted for by including only the studied variables.
The effect of age
Age was a highly significant predictor of the antidepressant response to rTMS. This finding is consistent with previous research. In an open study with 56 patients, Figiel et al. (1998) showed that the antidepressant response rate was higher for younger (<65 yr) compared to older patients (56 % vs. 23 %) ; see also Epstein et al., 1998) . In addition, two other studies have reported that elderly patients have no significant antidepressant response to TMS compared to placebo (Manes et al., 2001 ; Mosimann et al., 2004) . Nahas et al. (2004) hypothesized that this lack of effect in the elderly is due to frontal atrophy and conducted a pilot study that showed that TMS treatment adjusted for the prefrontal atrophy is associated with a significant antidepressant effect (Nahas et al., 2004) . This finding would explain why younger patients responded more than older patients as the TMS intensity in these past studies was not adjusted for prefrontal atrophy. Another potential explanation to account for the decreased response in elderly patients is a general refractoriness of these patients to any type of antidepressant treatment. However, elderly patients may have a good response to ECT, although ECT clinical trials tend to have a relatively low number of elderly patients (UK ECT Review Group, 2003) . There are few studies comparing the effects of antidepressants between older and younger patients, and these show mixed results. Whereas some studies show that antidepressants are equally effective in older compared to younger depressed patients (Gildengers et al., 2002 ; Martin et al., 1987) , others have reported decreased efficacy of these drugs in the older population (Mulsant and Pollock, 1998 ; Zanardi et al., 2003) . One of the reasons for the different antidepressant response rate, based on the age of the patient, may be due to the atypical features that depression may display in the elderly and the association with other brain organic disorders. Furthermore, late-life depression has been associated with a chronic course that may be less responsive to medical treatment. However, this fact seems unlikely to explain our findings as we controlled for treatment refractoriness and tested for depression duration in our model as well.
Finally, the lower antidepressant response of older patients to TMS could be due to a slower response of older patients compared to younger patients as we only evaluated the acute response (after 2 wk of treatment) and did not include the follow-up evaluation in our model. Indeed, past research has shown that depressive symptoms continue to decrease after the cessation of rTMS (Koerselman et al., 2004) and the effects of antidepressants may be slower in elderly patients (Zanardi et al., 2003) . If this is the case, future rTMS trials should have a long-term follow-up to evaluate this possible delayed antidepressant effect in elderly patients.
The effect of treatment refractoriness
Treatment refractoriness was another significant predictor in our model after adjusting for the other significant variables and potential confounders. This finding seems to be intuitive, as patients refractory to antidepressants might have a more severe form of depression and be also resistant to the antidepressant effects of rTMS. In fact, medication resistance can also decrease ECT antidepressant effect magnitude (UK ECT Review Group, 2003) . However, the mechanisms of action of rTMS may differ from those of antidepressant medications. Despite the fact that past research suggests that rTMS may act on neurotransmitter levels, similarly to antidepressants (BenShachar et al., 1997) , this is not the only rTMS mechanism of action that has been proposed as it has been shown that this therapy can increase the metabolism of the cortical stimulated area (Mottaghy et al., 2003) and exert network-specific effects in cortical and subcortical structures bihemispherically. Therefore, the poor response of refractory depressed patients to rTMS might be due to similar pathophysiological mechanisms of rTMS and drugs or other TMS-specific
effects not yet known. This result yields two important implications for future clinical trials of rTMS treatment for depression. First, because rTMS has a greater effect in patients that are not refractory to medications, it should be further investigated in these patients (e.g. nonrefractory patients who are not willing to take antidepressant medications or have contraindications to these drugs). Second, the smaller effect of rTMS in refractory patients might indicate that the rTMS treatment for these patients needs to be prolonged, i.e. 'higher rTMS dosage', thus, future clinical trials should address this issue, adjusting rTMS dosage according to patients' status (refractory vs. nonrefractory).
Some methodological considerations
This study has some methodological issues that should be addressed. Some potential important predictors and unmeasured confounders for antidepressant response might not have been included in our model. Our models, however, had a satisfactory R 2 (0.44, 0.39 and 0.38) and hence could predict up to 44 % of the data variability. Furthermore, the patients enrolled into each of these six studies consented to participate in a clinical trial evaluating a new tool for depression treatment, therefore, this sample may not be representative of the general population of depressive patients, and thus our findings may not be externally generalized to other patients with depression.
The effects of the predictors of age and refractoriness might not be specific for rTMS as our model did not evaluate the effects of other treatments such as antidepressants or placebo. Another potential limitation is that these six studies were slightly different regarding the criteria of refractoriness. Whereas some of these studies classified patients as refractory if they failed to respond to three antidepressants, others defined this threshold as failing to respond to only two antidepressants. We do not believe that these criteria biased our results as the number of failed medications might not be correlated to the degree of refractoriness and most of the patients that were refractory to at least one drug were refractory to several drugs.
Finally, the six studies that were included in our analysis had different methodologies, such as differences in rTMS parameters and population sample. In order to account for this confounder, we controlled for study site. These differences, however, might not have been fully accounted for and, therefore, the results of this study have to be interpreted with caution.
Conclusions
Based on the finding that rTMS can cause a greater antidepressant effect in younger and non-refractory patients, further clinical trials should study the effects of rTMS early in antidepressant treatment and in young patients who are unwilling to take antidepressants or have contraindications to these drugs. These findings, therefore, might assist in designing future studies using rTMS for the treatment of depression.
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